The pace of innovation across cell and gene therapy biotechs is gaining speed and it can be challenging to keep track of scientific developments, new technologies and who might be looking for their next big partnership.
Where is the innovation happening in our industry?
Whose pipelines are showing promise of an approved product in 2020?
More importantly, whose will succeed in the market?
Without innovation, infrastructure and investment, advanced therapies will not succeed as commercially viable products. The innovation of science, manufacturing processes, payment and reimbursement and talent development are all critical success factors.
Phacilitate's biennial 'Top 20 Advanced Therapy Biotechs to Watch' e-book is a collection of 20 of the most innovative and exciting biotechs to watch over the coming year, curated with input from industry nominations, the Phacilitate:Exchange editorial board and Phacilitate.
Of course, we're impartial so here's the list in alphabetical order...